Sign inJoin waitlistJoin the waitlist

Michael E. Wechsler

Critical Care Medicine · National Jewish Health

Credentials: · · · · · · ·

History

Brigham and Women’s Hospital
1998–1999
Beth Israel Medical Center, Brigham and Women’s Hospital, Massachusetts General Hospital
1996–1998
1995–1996
Beth Israel Hospital
1994–1996
Beth Israel Hospital
1993–1994
McGill University School of Medicine
1989–1993

Research

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3…
The Lancet Respiratory Medicine · 2015 · 893 citations
Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma
New England Journal of Medicine · 2021 · 844 citations
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
New England Journal of Medicine · 2017 · First of 19 authors · 801 citations

EI
Elliot Israel
78 papers
Mario Castro
49 papers
Monica Kraft
41 papers
SP
Stephen Peters
34 papers
Stephen Lazarus
32 papers
NL
Njira Lugogo
31 papers
Christine Sorkness
30 papers
Eileen Wang
27 papers
Praveen Akuthota
27 papers
Stanley Szefler
25 papers
Homer Boushey
24 papers
RL
Robert Lemanske
24 papers

Grants

1/2 Precision Tapering of Biologic Therapy in Asthma: Identifying Predictors of Successful Dupilumab Interval Extension
National Heart, Lung, and Blood Institute · UG3
Contact PI · $2.1M · National Jewish Health
2026–2027
Precision Interventions for Severe and/or Exacerbation Prone Asthma (PrecISE)
National Heart, Lung, and Blood Institute · UG1
Contact PI · $2.3M · National Jewish Health
2017–2024
Anti IL5 and Churg Strauss Syndrome: A Double Blind, Placebo Controlled Trial
National Institute of Allergy and Infectious Diseases · U01
Contact PI · $5.8M · National Jewish Health
2013–2020
Clinical Centers for the NHLBI Asthma Network (AsthmaNet)
National Heart, Lung, and Blood Institute · U10
Contact PI · $1M · National Jewish Health
2009–2018

Clinical trials

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
Principal investigator · Terminated · Phase 3
Areteia Therapeutics
2023–2025
Reslizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Principal investigator · Recruiting · Phase 2
National Jewish Health
2017–2018
Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study
Principal investigator · Active not recruiting · Phase 2
National Jewish Health
2017–2021
Mepolizumab As a Steroid-sparing Treatment Option in the Churg Strauss Syndrome
Principal investigator · Completed · Phase 1, Phase 2
Brigham and Women's Hospital
2007–2009